NFE2L2 and neuroblastoma: In addition, bortezomib has been demonstrated to exert cytotoxicity by increasing ROS production [228] and, in this context, our recent studies have shown that bortezomib treatment of human neuroblastoma cells is less effective as a consequence of Nrf2-mediated HO-1 upregulation [85].